Advanced Oncotherapy the end goal is very much in sight (Analyst Interview)

Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk. Martin explains what’s been happening with the company lately, the potential advantages of LIGHT, how close we are to the first system, how AVO is funding all the work and what investors and potential investors can look forward to over the coming months.

Advanced Oncotherapy is a specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, which is the result of 25 years of work at CERN and ADAM.

Its focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient’s healthy tissues.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly de-risked the

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked through important

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up to date

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked